US Diabetic Retinopathy Increase: Statement From American Academy Of Ophthalmology

The American Academy of Ophthalmology (Academy) considers this study reliable evidence that diabetic retinopathy and vision-threatening diabetic retinopathy are increasing in adults over age 40 in the United States and that more Americans, especially non-Hispanic black Americans, will be vulnerable to potentially-blinding diabetic retinopathy in coming...

American Academy Of Ophthalmology: Body Weight May Affect Glaucoma Risk; A New ‘Map’ Of Severe Nearsightedness May Help Diagnosis, Treatment

This month's Ophthalmology includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for...

iCo Therapeutics Inc. Receives Health Canada Clearance To Conduct Phase II DME Trial With iCo-007

iCo Therapeutics Inc. (TSX VENTURE:ICO) is pleased to announce that the Therapeutic Products Directorate, a division of Health Canada, has issued a No Objection Letter response to the Company regarding its iCo-007 Phase II Diabetic Macular Edema (DME) Clinical Trial Application...

pSivida Announces Submission Of MAA For An Ophthalmic Product For Diabetic Macular Edema In Certain European Union Countries

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for...

Phase 3 Study Showed MACUGEN(R) Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema

Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working...

Phase 3 Study Presented At World Ophthalmology Congress Evaluates Investigational Use Of Macugen In Patients With Diabetic Macular Edema

Eyetech Inc. announced that positive results from a Phase 3 study of Macugen® (pegaptanib sodium) in patients with diabetic macular edema (DME) were presented at the World Ophthalmology Congress in...

Los Angeles Latino Eye Study Is First To Track Eye Disease Incidence In Latino Population

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United...

Diabetic Retinopathy Clinical Research Network Study Finds New Treatment More Effective

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration...

New Treatment For Diabetic Macular Edema Confirmed By Comparative-Effectiveness Study

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina. Laser treatment alone has been the standard care for the past 25...